What You Should Know:
Quest Diagnostics has reached an agreement to acquire Haystack Oncology an early-stage oncology company focused on minimal residual disease (MRD) testing to aid in the early, accurate detection of residual or recurring cancer and better inform therapy decisionsUnder the terms of the agreement, Quest will pay $300 million in cash at closing, net of cash acquired, and up to an additional $150 million on achieving future performance
Read More
Oncology Technology Solutions, Services Impacting Patients and Providers
Report: Prior Authorization for Biomarker Testing Leads to Treatment Delays For Cancer Patients
What You Should Know:
Biomarker testing is a necessary tool in the advancing world of precision cancer treatment. According to a new survey released by CancerCare, a leading national cancer support organization, biomarker testing helped doctors tailor therapy for nearly all the respondent patients (93%) whose cancers were tested over the past three years. Two in 10 cancer patients (20%) surveyed were able to avoid unnecessary chemotherapy and/or radiation and 10% became eligible for
Read More
Exec Hires: COTA Appoints First Chief Commercial Officer
What You Should Know:
- COTA, Inc., an oncology real-world data and analytics company, today announced the appointment of Sandy Leonard as its first Chief Commercial Officer.
- As CCO, Sandy will drive COTA’s life sciences growth strategy, prioritizing customer success and experience. More specifically, she will lead a team that is laser-focused on ensuring that pharmaceutical partners have the data assets, analytics, services, and support they need to develop life-saving
Read More
Inato Raises $20M to Make Clinical Trials More Inclusive
What You Should Know:
- Inato, a technology platform that connects pharma companies (trial sponsors) with community-based trial sites raises $20M in new funding (A2) led by Cathay Innovation with participation from existing investor Obvious Ventures and new investors La Maison and Top Harvest Capital. Inato works with many of the top 30 pharmaceutical companies worldwide to make clinical trials more inclusive.
- The new funding will fuel Inato’s continued product innovation, international
Read More
Genialis Raises $13M to Build Clinical Biomarkers that Predict Patient Response
What You Should Know:
Genialis, a computational precision medicine company unraveling complex biology to find new ways to address disease, today announced it raised more than $13 million in Series A financing to transform the way diseases are diagnosed and treatment decisions are made.Taiwania Capital and Debiopharm Innovation Fund co-led the round, with participation from previous investors First Star Ventures, Redalpine Venture Partners, and Pikas. Other new investors include P5 Health
Read More
Interoperability: Particle Health Launches Suite of Solutions to Wrangle Data
What You Should Know:
- Particle Health, an interoperability platform that aggregates and delivers actionable patient data and insights to healthcare companies, announced today it has launched its Particle FOCUS (Filtered Outputs Curated for Usability + Simplicity) solution suite.
- FOCUS data products are designed to streamline data by delivering comprehensive, simplified, and organized patient health information across seven disease states:
Read More
Digital Health Exec Hires: Transcarent Appoints CMO, Carium, Tegria, Swift Medical, GoCheckKids, Others
Transcarent appoints Dr. Randy Hawkins as Chief Medical Officer (CMO) and will report to Transcarent Chief Executive Officer, Glen Tullman. As CMO, Dr. Hawkins will oversee the organization’s clinical quality initiatives and support the organization’s health analytics strategy.
Swift Medical has appointed Brian Litten as its new Chief Executive Officer effective immediately. Litten brings decades of healthcare leadership experience across health plans, provider organizations, regulatory
Read More
Accelerating Clinical Trials Through AI-Enabled Precision Oncology
The American Cancer Society’s Cancer Statistics 2023 report highlighted a few major accomplishments within oncology, such as decreased cancer mortality rates and increased trial diversity. However, there is still much work to be done. Especially with the multiple types of new and ongoing challenges clinicians and staff members are facing - such as high turnover rates, decreased budgets and increased feelings of burnout - taking the necessary steps to enhance clinical trial procedures is crucial
Read More
Accenture: Data Collaboratives Hold Great Promise for Accelerated Healthcare Progress and Precision Medicine
What You Should Know:
- Accenture published Fast-Forwarding Healthcare through Data Collaboratives Report to discover how best health ecosystem players access data to fast-forward healthcare.
- Data generated by technical and scientific advances, like connected health devices, consumer health and medical-grade digital apps, individual multi-omics profiling data and the move to cloud storage, holds great promise for accelerated healthcare progress and precision medicine, and data
Read More
Protai Raises $20M to Build an Oncology Drug Discovery Pipeline
What You Should Know:
- Protai, a proteomics and AI-powered drug discovery startup revolutionizing the way new drugs are discovered, today announced a $12 million extension of its seed round, bringing the total amount to $20M.
- The round includes existing investors Grove Ventures and Pitango Healthcare and was joined by Copenhagen-based Maj Invest Equity Fund. The additional funding will be used to build Protai’s oncology drug discovery pipeline, expand data
Read More
